
    
      The aim is to demonstrate whether leading edge molecular imaging technologies (FDG-PET/CT,
      DW-MRI and Fluoro-ethyl-choline (FEC) PET/CT) can identify lymph node metastases with
      sufficient accuracy to allow non-invasive lymph node staging in patients with endometrial and
      cervical carcinoma.
    
  